These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 7006415)

  • 1. Increased enzymatic activity of renin and hyperlipidemia.
    Kotchen TA; Talwalkar RT
    Am J Physiol; 1981 Jan; 240(1):E60-4. PubMed ID: 7006415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modification of renin reactivity by lipids extracted from normal, hypertensive, and uremic plasma.
    Kotchen TA; Talwalker RT; Miller MC; Welch WJ
    J Clin Endocrinol Metab; 1976 Nov; 43(5):971-81. PubMed ID: 186481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzymatic activity of renin in plasma of normal and uraemic subjects.
    Kotchen TA; Guyenne TT; Corvol P; Menard J
    Clin Sci (Lond); 1984 Sep; 67(3):365-8. PubMed ID: 6380890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different mechanisms for the increased enzymatic activity of renin in plasma of patients with chronic renal failure and patients receiving glucocorticoid therapy.
    Talwalkar RT; Kotchen TA; Welch WJ; Curtis JJ; Galla JH
    J Clin Endocrinol Metab; 1980 Jun; 50(6):989-93. PubMed ID: 6989853
    [No Abstract]   [Full Text] [Related]  

  • 5. Renal venous plasma renin reactivity in clinical and experimental renovascular hypertension: renin reactivity in renovascular hypertension.
    Kotchen TA; Welch WJ; Daugherty M; Ernst CB
    Nephron; 1977; 19(4):228-35. PubMed ID: 917170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for the existence of an acetone soluble renin inhibiting factor in normal human plasma.
    Kotchen TA; Talwalkar RT; Kotchen JM; Miller MC; Welch WJ
    Circ Res; 1975 Jun; 36(6 Suppl 1):17-27. PubMed ID: 1132076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of renin inhibitors in normal and uremic plasma.
    Kotchen TA; Talwalkar RT; Kaul K
    J Lab Clin Med; 1985 Mar; 105(3):286-93. PubMed ID: 3882863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renin reactivity in plasma of patients with normal renin and low renin essential hypertension.
    Brooks CS; Talwalker RT; Kotchen TA
    J Clin Endocrinol Metab; 1977 Feb; 44(2):322-9. PubMed ID: 838842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clofibrate treatment of hyperlipidemia in chronic renal failure.
    di Giulio S; Boulu R; Drüeke T; Nicolaĭ A; Zingraff J; Crosnier J
    Clin Nephrol; 1977 Dec; 8(6):504-9. PubMed ID: 598055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence against acetone-soluble renin inhibitors in normal human plasma.
    Druilhet RE; Overturf ML; Hinshaw RA; Kirkendall WM
    Hypertension; 1979; 1(2):98-105. PubMed ID: 399942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating renin Angiotensin system in childhood chronic renal failure: marked increase of Angiotensin-(1-7) in end-stage renal disease.
    Simões e Silva AC; Diniz JS; Pereira RM; Pinheiro SV; Santos RA
    Pediatr Res; 2006 Dec; 60(6):734-9. PubMed ID: 17065573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Renal tissue angiotensins during converting enzyme inhibition of angiotensin I in spontaneously hypertensive rat].
    Ingert C; Grima M; Michel B; Barthelmebs M; Imbs JL
    Arch Mal Coeur Vaiss; 1997 Aug; 90(8):1135-41. PubMed ID: 9404423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of plasma renin activity as a valid estimation of plasma angiotensin status.
    Roulston JE; Macgregor GA; Adam T; Markandu ND
    Ann Clin Biochem; 1978 Sep; 15(5):250-2. PubMed ID: 718108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variable effects of soy protein on plasma lipids in hyperlipidemic and normolipidemic hemodialysis patients.
    Chen ST; Ferng SH; Yang CS; Peng SJ; Lee HR; Chen JR
    Am J Kidney Dis; 2005 Dec; 46(6):1099-106. PubMed ID: 16310576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tryptic activation of plasma renin activity.
    Noth RH; Cariski AT; Havelick J
    J Clin Endocrinol Metab; 1980 Jun; 50(6):983-8. PubMed ID: 6768764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endogenous angiotensin I concentration in human plasma.
    Lijnen PJ; Amery AK; Fagard RH
    J Lab Clin Med; 1978 Sep; 92(3):353-62. PubMed ID: 28372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
    van de Wal RM; Plokker HW; Lok DJ; Boomsma F; van der Horst FA; van Veldhuisen DJ; van Gilst WH; Voors AA
    Int J Cardiol; 2006 Jan; 106(3):367-72. PubMed ID: 16337046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease.
    Chapman AB; Johnson A; Gabow PA; Schrier RW
    N Engl J Med; 1990 Oct; 323(16):1091-6. PubMed ID: 2215576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impaired control of plasma renin activity in hypertensive patients with end-stage renal disease due to chronic glomerulonephritis.
    Yasuda G; Nagasawa T; Umemura S; Shionoiri H; Ishii M
    Clin Nephrol; 1994 Nov; 42(5):300-8. PubMed ID: 7851031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans.
    Fisher ND; Jan Danser AH; Nussberger J; Dole WP; Hollenberg NK
    Circulation; 2008 Jun; 117(25):3199-205. PubMed ID: 18559696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.